Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
RINVOQ ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved […]
Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma
Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed […]
Life-extending Injection for Blood Cancer Available on the NHS
A life-extending injection for a fatal form of blood cancer will be available to around […]
New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for Evrysdi® (risdiplam) in spinal muscular atrophy […]
Seabelife Receives Close to €1.4m Deep Tech Financing from Bpifrance
SeaBeLife, a biotech company developing drug candidates intended to block cell necrosis, today announces that […]
Index Pharmaceuticals Prepares for Commercialisation of Cobitolimod
InDex Pharmaceuticals Holding AB (publ)is planning for self-commercialisation of the drug candidate cobitolimod in the […]
Impact Therapeutics Announces Completion of Series D1 Financing
IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics […]
Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health
Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription […]
Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-oncology
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting […]
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more